Neimeth International Pharmaceuticals (NEIMETH) Stock Overview
Manufactures and markets pharmaceutical and animal health products in Nigeria and Ghana. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NEIMETH Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Neimeth International Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₦12.60 |
| 52 Week High | ₦16.15 |
| 52 Week Low | ₦2.42 |
| Beta | 0.75 |
| 1 Month Change | 24.14% |
| 3 Month Change | 133.33% |
| 1 Year Change | 293.75% |
| 3 Year Change | 712.90% |
| 5 Year Change | 477.98% |
| Change since IPO | 515.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEIMETH | NG Pharmaceuticals | NG Market | |
|---|---|---|---|
| 7D | 13.5% | 0.06% | 6.3% |
| 1Y | 293.8% | -1.9% | 76.7% |
Return vs Industry: NEIMETH exceeded the NG Pharmaceuticals industry which returned -1.9% over the past year.
Return vs Market: NEIMETH exceeded the NG Market which returned 76.7% over the past year.
Price Volatility
| NEIMETH volatility | |
|---|---|
| NEIMETH Average Weekly Movement | 13.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in NG Market | 11.4% |
| 10% least volatile stocks in NG Market | 4.1% |
Stable Share Price: NEIMETH's share price has been volatile over the past 3 months compared to the NG market.
Volatility Over Time: NEIMETH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of NG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 175 | J. Valentine Okelu | www.neimethplc.com.ng |
Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical and animal health products in Nigeria and Ghana. It provides health care, ethical, and veterinary related products; and poultry and animal range of anthelmintic products, as well as production enhancing medicaments. The company was formerly known as Pfizer Inc. and changed its name to Neimeth International Pharmaceuticals Plc.
Neimeth International Pharmaceuticals Plc Fundamentals Summary
| NEIMETH fundamental statistics | |
|---|---|
| Market cap | ₦55.12b |
| Earnings (TTM) | ₦982.11m |
| Revenue (TTM) | ₦7.37b |
Is NEIMETH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEIMETH income statement (TTM) | |
|---|---|
| Revenue | ₦7.37b |
| Cost of Revenue | ₦4.06b |
| Gross Profit | ₦3.31b |
| Other Expenses | ₦2.33b |
| Earnings | ₦982.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 44.96% |
| Net Profit Margin | 13.33% |
| Debt/Equity Ratio | 367.6% |
How did NEIMETH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 18:12 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neimeth International Pharmaceuticals Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Meristem Securities Limited |